Harlequins has announced a new partnership with antiviral nasal spray VIRALEZE, which the club says it will use as one part of its suite of measures put in place to help protect its players and coaching staff.
Starpharma - the maker of the VIRALEZE brand - says the spray has been shown in lab studies to ‘inactivate’ more than 99.9% of respiratory viruses, including COVID-19, but also the likes of common cold viruses and influenza.
The club says it will use the product as one tool in its armoury for keeping its players safe from all viruses and illnesses.
“Player health is paramount in professional sport and now more than ever, we look to maximise the level of protection we can offer our players,” said Mike Lancaster, Head of Medical Services, Harlequins.
“The VIRALEZE partnership is an important additional level of protection for our men’s and women’s players against viruses such as flu and coronavirus SARS-CoV-2.